On 26th Aug 2025, Hon’ble Prime Minister Shri Narendra Modi inaugurated the start of production of Maruti Suzuki’s first Battery Electric Vehicle (BEV), the e-Vitara, at Suzuki Motor Gujarat Private Limited (SMG), a wholly owned subsidiary of Maruti Suzuki India.
We have revised our FY26E/FY27E EPS estimates by -5.7%/-1.9%, as we factor in weaker EBITDA margins led by contraction in gross margins. We reiterate our “ACCUMULATE” rating on the stock, supported by its volume-led growth strategy. We expect margin pressure to remain persistent in the near term but expect gradual recovery from H2FY26E onwards
Vikran’s initial issue is available at 17.3x TTM EV/EBITDA which is much lower to its peer average of 32.0x TTM EV/EBITDA. We believe the issue is attractively priced, as its growth in terms of revenue and EBITDA, has trended in a similar range of its peers, while it is available at a much lower valuation. We assign a “SUBCRIBE” rating to the issue.
We have revised our FY26E/FY27E EPS estimates by +2.6%/-7.4% as we bake in slower revenue growth as Revlimid and Mirabegron sales is expected to taper-off and factor in a marginal increase in EBITDA margins in FY26, while we factor in weaker margins on the back of changing product mix towards competitive generics over FY27.
We have revised our FY26E/FY27E EPS estimates by -22.3%/-17.0%, as we factor in stronger momentum in revenue growth, weaker EBIT margins led by higher processing charges, higher other income on idle reserves and increase in outstanding shares on account of right issue.
We maintain a constructive stance on Vinati Organics’ long-term outlook, supported by the expansion in ATBS capacities, improved utilization in Antioxidant segment and incremental contribution from the Veeral Organics facility, cementing its position in high-margin segments, leading to improved operating leverage and diversified revenue streams.
We have revised our FY26E/FY27E EBITDA estimates by -9.3%/-3.3%, as we factor in more gradual pick-up in consumer demand and higher input costs in FY26, led by online marketing projects undertaken by the Company.
We have revised our FY26E/FY27E EPS estimates by -4.4%/-9.0% factoring in a miss in Q1FY26 performance, slower-than-expected recovery in exports due to prolonged customer destocking, and regulatory headwinds in biologicals that have curtailed domestic growth.
We have revised our FY26E/FY27E EPS estimates by -3.8%/+0.3% primarily to reflect miss in the Q1FY26 performance, and higher depreciation expenses, however, FY27 numbers are intact with rising regulated market share, enhanced backward integration, scale-up of the DSM contract, and new launches such as contrast media and ADHD APIs.
We have revised our FY26E/FY27E EPS estimates by -0.6%/-4.6% primarily to reflect a more gradual post-remediation ramp-up at Gagillapur, and a measured margin recovery amid persistent integration and operating costs.
